In myeloma, PI3K inhibitors preferentially suppressed PTEN-null myeloma growth to those expressing PTEN, indicating that PI3K activation is more critical for growth and survival of those lines with PTEN mutations than others expressing a functional PTEN gene [374]. The gene discussed is PTEN; the disease is plasma cell myeloma.